Septerna, Inc. is a clinical-stage biotechnology company that leverages its proprietary Native Complex Platform to pioneer oral small molecule drug discovery targeting G protein-coupled receptors (GPCRs). The company's platform reconstitutes GPCRs outside of cells, enabling the discovery of novel therapeutics for historically undruggable or challenging targets. Septerna's pipeline includes SEP-786 and SEP-479, which are oral small molecule Parathyroid Hormone 1 Receptor (PTH1R) agonists for the treatment of hypoparathyroidism. Additionally, the company is advancing SEP-631 for chronic spontaneous urticaria and other mast cell diseases, alongside programs targeting thyroid diseases. Founded in 2019 and headquartered in South San Francisco, California, Septerna also maintains a strategic collaboration with Novo Nordisk to develop therapies for metabolic diseases.
